<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="35328f75-ef53-4566-e063-6394a90a9e72"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use VASOPRESSIN INJECTION safely and effectively. See full prescribing information for VASOPRESSIN INJECTION.
 <br/>
      <br/>
VASOPRESSIN injection, for intravenous use
 <br/>
Initial U.S. Approval: 2014
</title>
   <effectiveTime value="20250515"/>
   <setId root="3532868c-ac1d-43c8-e063-6394a90a4fd1"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="601458529"/>
            <name>Medical Purchasing Solutions, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="601458529"/>
                        <name>Medical Purchasing Solutions, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="71872-7334" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3532b4b6-8ffa-5aaf-e063-6394a90a9186"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250515"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71872-7334" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>vasopressin</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Vasopressin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="43598-914" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4550K0SC9B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ACETATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="[USP'U]" value="20"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="Y87Y826H08" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VASOPRESSIN, UNSPECIFIED</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="Y87Y826H08" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VASOPRESSIN, UNSPECIFIED</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71872-7334-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BAG"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20241116"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA213988" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240509"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_db582c43-0dcf-406a-b744-fc03d6c2f2f8">
               <id root="3532879b-0375-4201-e063-6394a90a9cbd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.</paragraph>
               </text>
               <effectiveTime value="20240731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. (
  
     <linkHtml href="#LINK_db582c43-0dcf-406a-b744-fc03d6c2f2f8">1</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_fffa92d0-14c4-48d3-8918-4911ea6e0f0e">
               <id root="3532879b-0376-4201-e063-6394a90a9cbd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20240731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Dilute 20 units/mL single dose vial contents with normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) to either 0.1 units/mL or 1 unit/mL for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration. (
  
     <linkHtml href="#LINK_26303185-d003-47a2-8abe-76d2dfe4d4a0">2.1</linkHtml>)
 
    </item>
                           <item>Post-cardiotomy shock: 0.03 to 0.1 units/minute (
  
     <linkHtml href="#LINK_859ae74a-30a2-4b7d-84b5-e18464aa3f9f">2.2</linkHtml>)
 
    </item>
                           <item>Septic shock: 0.01 to 0.07 units/minute (
  
     <linkHtml href="#LINK_859ae74a-30a2-4b7d-84b5-e18464aa3f9f">2.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_26303185-d003-47a2-8abe-76d2dfe4d4a0">
                     <id root="3532879b-0377-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Preparation of Solution</title>
                     <text>
                        <paragraph>Inspect parenteral drug products for particulate matter and discoloration prior to use, whenever solution and container permit.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Vasopressin</content>
                           <content styleCode="bold">Injection Solution for Dilution, 20 units/mL</content>
                        </paragraph>
                        <paragraph>Dilute vasopressin injection in normal saline (0.9% sodium chloride) or 5% dextrose in water (D5W) prior to use for intravenous administration. Discard unused diluted solution after 18 hours at room temperature or 24 hours under refrigeration.</paragraph>
                        <table>
                           <caption>Table 1 Preparation of diluted solutions</caption>
                           <col width="22%"/>
                           <col width="1px"/>
                           <col width="1px"/>
                           <col width="1px"/>
                           <thead>
                              <tr>
                                 <th align="center" rowspan="2" styleCode="Toprule Lrule Rrule" valign="top">
                                    <content styleCode="bold">Fluid restriction?</content>
                                 </th>
                                 <th align="center" rowspan="2" styleCode="Toprule Rrule" valign="top">
                                    <content styleCode="bold">Final concentration</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Botrule Toprule Rrule" valign="top">
                                    <content styleCode="bold">Mix</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Botrule Lrule Rrule" valign="top">V
    
     <content styleCode="bold">asopressin Injection</content>
                                 </th>
                                 <th align="center" styleCode="Botrule Rrule" valign="top">
                                    <content styleCode="bold">Diluent</content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td styleCode="Botrule Toprule Lrule Rrule" valign="top"> 
    
     <paragraph>No</paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule Rrule" valign="top"> 
    
     <paragraph>0.1 units/mL</paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule Rrule" valign="top"> 
    
     <paragraph>2.5 mL (50 units)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Toprule Rrule" valign="top"> 
    
     <paragraph>500 mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Botrule Lrule Rrule" valign="top"> 
    
     <paragraph>Yes</paragraph>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top"> 
    
     <paragraph>1 unit/mL</paragraph>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top"> 
    
     <paragraph>5 mL (100 units)</paragraph>
                                 </td>
                                 <td styleCode="Botrule Rrule" valign="top"> 
    
     <paragraph>100 mL</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_859ae74a-30a2-4b7d-84b5-e18464aa3f9f">
                     <id root="3532879b-0378-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Administration</title>
                     <text>
                        <paragraph>In general, titrate to the lowest dose compatible with a clinically acceptable response.</paragraph>
                        <paragraph>The recommended starting dose is:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Post-cardiotomy shock:</content>0.03 units/minute

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Septic Shock:</content>0.01 units/minute

 </paragraph>
                        <paragraph>Titrate up by 0.005 units/minute at 10 -to 15-minute intervals until the target blood pressure is reached. There are limited data for doses above 0.1 units/minute for post-cardiotomy shock and 0.07 units/minute for septic shock. Adverse reactions are expected to increase with higher doses.</paragraph>
                        <paragraph>After target blood pressure has been maintained for 8 hours without the use of catecholamines, taper vasopressin injection by 0.005 units/minute every hour as tolerated to maintain target blood pressure.</paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bd8a1cec-2c62-43b4-8bc0-6c331d44bdbb">
               <id root="3532879b-0379-4201-e063-6394a90a9cbd"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Vasopressin injection, USP is a colorless solution for intravenous administration available as 20 units/mL in a single dose vial. To be used after dilution.</paragraph>
               </text>
               <effectiveTime value="20240731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Injection: 20 units per mL in a single dose vial. To be used after dilution. (
  
     <linkHtml href="#LINK_bd8a1cec-2c62-43b4-8bc0-6c331d44bdbb">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_461079aa-3cc7-4b03-b912-cc6b7a261f8f">
               <id root="3532879b-037a-4201-e063-6394a90a9cbd"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Vasopressin injection 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin.</paragraph>
               </text>
               <effectiveTime value="20240731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Vasopressin injection 1 mL single dose vial does not contain chlorobutanol and is therefore contraindicated only in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin. (
  
     <linkHtml href="#LINK_461079aa-3cc7-4b03-b912-cc6b7a261f8f">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_affc0ee0-13dc-40e3-a15e-d9e923566ad4">
               <id root="3532879b-037b-4201-e063-6394a90a9cbd"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Can worsen cardiac function. (
  
     <linkHtml href="#LINK_ebafc376-7261-4310-b5e4-9754f04ba594">5.1</linkHtml>)
 
    </item>
                           <item>Reversible diabetes insipidus (
  
     <linkHtml href="#_18f51fdb-38bb-733a-c5f1-f9950e0a7c73">5.2</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_ebafc376-7261-4310-b5e4-9754f04ba594">
                     <id root="3532879b-037c-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Worsening Cardiac Function</title>
                     <text>
                        <paragraph>A decrease in cardiac index may be observed with the use of vasopressin.</paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="_18f51fdb-38bb-733a-c5f1-f9950e0a7c73">
                     <id root="3532879b-037d-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Reversible Diabetes Insipidus</title>
                     <text>
                        <paragraph>Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.</paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_7fb1ac43-6efa-400d-86d0-4b316ec16ba7">
               <id root="3532879b-037e-4201-e063-6394a90a9cbd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of vasopressin were identified in the literature. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>Bleeding/lymphatic system disorders: Hemorrhagic shock, decreased platelets, intractable bleeding</paragraph>
                  <paragraph>Cardiac disorders: Right heart failure, atrial fibrillation, bradycardia, myocardial ischemia</paragraph>
                  <paragraph>Gastrointestinal disorders: Mesenteric ischemia</paragraph>
                  <paragraph>Hepatobiliary: Increased bilirubin levels</paragraph>
                  <paragraph>Renal/urinary disorders: Acute renal insufficiency</paragraph>
                  <paragraph>Vascular disorders: Distal limb ischemia</paragraph>
                  <paragraph>Metabolic: Hyponatremia</paragraph>
                  <paragraph>Skin: Ischemic lesions</paragraph>
                  <paragraph>
                     <content styleCode="bold">Postmarketing Experience</content>
                  </paragraph>
                  <paragraph>Reversible diabetes insipidus
 
  <content styleCode="italics">[see Warnings and Precautions (
  
   <linkHtml href="#_18f51fdb-38bb-733a-c5f1-f9950e0a7c73">5.2</linkHtml>)]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20240731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital). (
 
    <linkHtml href="#LINK_7fb1ac43-6efa-400d-86d0-4b316ec16ba7">6</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_940f33d3-61d0-46da-989d-cbe415ab41df">
               <id root="3532879b-037f-4201-e063-6394a90a9cbd"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20230401"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Pressor effects of catecholamines and vasopressin injection are expected to be additive. (
  
     <linkHtml href="#LINK_ea666767-809b-4ed8-adb5-205b808e9c53">7.1</linkHtml>)
 
    </item>
                           <item>Indomethacin may prolong effects of vasopressin injection. (
  
     <linkHtml href="#LINK_a1c0a11b-dc25-4d5c-96d7-9fe5d1d2bfed">7.2</linkHtml>)
 
    </item>
                           <item>Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response. (
  
     <linkHtml href="#LINK_9a0f84aa-ebea-4304-b03c-d95251cee824">7.3</linkHtml>,
  
     <linkHtml href="#LINK_1725ee26-0d55-4140-831d-21d748a10faa">7.4</linkHtml>)
 
    </item>
                           <item>Co-administration of drugs causing diabetes insipidus may decrease the pressor response. (
  
     <linkHtml href="#LINK_ed7e515a-85c4-4f03-8c51-35fb062cfc39">7.5</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_ea666767-809b-4ed8-adb5-205b808e9c53">
                     <id root="3532879b-0380-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Catecholamines</title>
                     <text>
                        <paragraph>Use with
 
  <content styleCode="italics">catecholamines</content>is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

 </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a1c0a11b-dc25-4d5c-96d7-9fe5d1d2bfed">
                     <id root="3532879b-0381-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Indomethacin</title>
                     <text>
                        <paragraph>Use with
 
  <content styleCode="italics">indomethacin</content>may prolong the effect of vasopressin injection on cardiac index and systemic vascular resistance. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_e92904f5-b767-4f54-b7a5-539ba6804e9c">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9a0f84aa-ebea-4304-b03c-d95251cee824">
                     <id root="3532879b-0382-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Ganglionic Blocking Agents</title>
                     <text>
                        <paragraph>Use with
 
  <content styleCode="italics">ganglionic blocking agents</content>may increase the effect of vasopressin injection on mean arterial blood pressure. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_e92904f5-b767-4f54-b7a5-539ba6804e9c">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1725ee26-0d55-4140-831d-21d748a10faa">
                     <id root="3532879b-0383-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Drugs Suspected of Causing SIADH</title>
                     <text>
                        <paragraph>Use with
 
  <content styleCode="italics">drugs suspected of causing SIADH</content>(e.g., SSRIs, tricyclic antidepressants, haloperidol, chlorpropamide, enalapril, methyldopa, pentamidine, vincristine, cyclophosphamide, ifosfamide, felbamate) may increase the pressor effect in addition to the antidiuretic effect of vasopressin injection. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

 </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ed7e515a-85c4-4f03-8c51-35fb062cfc39">
                     <id root="3532879b-0384-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Drugs Suspected of Causing Diabetes Insipidus</title>
                     <text>
                        <paragraph>Use with
 
  <content styleCode="italics">drugs suspected of causing diabetes insipidus</content>(e.g., demeclocycline, lithium, foscarnet, clozapine) may decrease the pressor effect in addition to the antidiuretic effect of vasopressin injection. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.

 </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_945925a6-2d55-46e5-9e72-61ac185d286d">
               <id root="3532879b-0385-4201-e063-6394a90a9cbd"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <content styleCode="bold">Pregnancy:</content>May induce uterine contractions. (
  
     <linkHtml href="#LINK_847bee89-2d93-42fa-a3fd-adfd21de3dac">8.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="bold">Pediatric Use:</content>Safety and effectiveness have not been established. (
  
     <linkHtml href="#LINK_0c72458b-def6-499a-a93b-99eec08d96ce">8.4</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="bold">Geriatric Use:</content>No safety issues have been identified in older patients. (
  
     <linkHtml href="#LINK_3c0379f0-b789-454d-ba6f-411d02a18d75">8.5</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_847bee89-2d93-42fa-a3fd-adfd21de3dac">
                     <id root="3532879b-0386-4201-e063-6394a90a9cbd"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on vasopressin injection use in pregnant women to inform a drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with vasopressin.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Dose adjustments during pregnancy and the postpartum period:</content>Because of increased clearance of vasopressin in the second and third trimester, the dose of vasopressin injection may need to be increased
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_859ae74a-30a2-4b7d-84b5-e18464aa3f9f">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical Pharmacology (
  
   <linkHtml href="#LINK_e92904f5-b767-4f54-b7a5-539ba6804e9c">12.3</linkHtml>)]
 
  </content>.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Maternal adverse reactions:</content> Vasopressin injection may produce tonic uterine contractions that could threaten the continuation of pregnancy.

 </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="_bf1b9088-9cce-7461-b654-065eb45814f6">
                     <id root="3532879b-0387-4201-e063-6394a90a9cbd"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>There are no data on the presence of vasopressin injection in either human or animal milk, the effects on the breastfed infant, or the effects on milk production.</paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0c72458b-def6-499a-a93b-99eec08d96ce">
                     <id root="3532879b-0388-4201-e063-6394a90a9cbd"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of vasopressin injection in pediatric patients with vasodilatory shock have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3c0379f0-b789-454d-ba6f-411d02a18d75">
                     <id root="3532879b-0389-4201-e063-6394a90a9cbd"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of vasopressin did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_affc0ee0-13dc-40e3-a15e-d9e923566ad4">Warnings and Precautions (5)</linkHtml>,
  
   <linkHtml href="#LINK_7fb1ac43-6efa-400d-86d0-4b316ec16ba7">Adverse Reactions (6)</linkHtml>, and
  
   <linkHtml href="#LINK_e92904f5-b767-4f54-b7a5-539ba6804e9c">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_cd4fd428-4d44-41f5-905d-0a6856f32235">
               <id root="3532879b-038a-4201-e063-6394a90a9cbd"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Overdosage with vasopressin injection can be expected to manifest as consequences of vasoconstriction of various vascular beds (peripheral, mesenteric, and coronary) and as hyponatremia. In addition, overdosage may lead less commonly to ventricular tachyarrhythmias (including Torsade de Pointes), rhabdomyolysis, and non-specific gastrointestinal symptoms.</paragraph>
                  <paragraph>Direct effects will resolve within minutes of withdrawal of treatment.</paragraph>
               </text>
               <effectiveTime value="20220401"/>
            </section>
         </component>
         <component>
            <section ID="LINK_dd1a103d-cffb-4de1-b44a-2894fada6705">
               <id root="3532879b-038b-4201-e063-6394a90a9cbd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Vasopressin is a polypeptide hormone. Vasopressin injection, USP is a sterile, aqueous solution of synthetic arginine vasopressin for intravenous administration.</paragraph>
                  <paragraph>The 1 mL solution contains vasopressin, USP 20 units/mL, 1.36 mg sodium acetate trihydrate and Water for Injection, USP. Sodium hydroxide and hydrochloric acid are included to adjust to a pH of ⁓3.8.</paragraph>
                  <paragraph>The chemical name of vasopressin is Cyclo (1-6) L-Cysteinyl-L-Tyrosyl-L-PhenylalanylL-Glutaminyl-L-Asparaginyl-L-Cysteinyl-L-Prolyl-L-Arginyl-L-Glycinamide. It is a white to off white powder/flakes, freely soluble in water. The structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Molecular Formula: C
 
  <sub>46</sub>H
 
  <sub>65</sub>N
 
  <sub>15</sub>O
 
  <sub>12</sub>S
 
  <sub>2</sub>                Molecular Weight: 1084.24 u

 </paragraph>
                  <paragraph>One mg is equivalent to 530 units.</paragraph>
               </text>
               <effectiveTime value="20220401"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4274ac98-904d-4eff-9199-54cab1c723fd">
               <id root="3532879b-038c-4201-e063-6394a90a9cbd"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220401"/>
               <component>
                  <section ID="LINK_fc954ca1-06a9-4790-90a4-7102f5baab6d">
                     <id root="3532879b-038d-4201-e063-6394a90a9cbd"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Vasopressin causes vasoconstriction by binding to V
 
  <sub>1</sub>receptors on vascular smooth muscle coupled to the Gq/11-phospholipase C-phosphatidyl-inositol-triphosphate pathway, resulting in the release of intracellular calcium. In addition, vasopressin stimulates antidiuresis via stimulation of V
 
  <sub>2</sub>receptors which are coupled to adenyl cyclase.

 </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9ca6eca0-5458-4c8d-814d-c029fe0d3bd6">
                     <id root="3532879b-038e-4201-e063-6394a90a9cbd"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>At therapeutic doses exogenous vasopressin elicits a vasoconstrictive effect in most vascular beds including the splanchnic, renal and cutaneous circulation. In addition, vasopressin at pressor doses triggers contractions of smooth muscles in the gastrointestinal tract mediated by muscular V
 
  <sub>1</sub>-receptors and release of prolactin and ACTH via V
 
  <sub>3</sub>receptors. At lower concentrations typical for the antidiuretic hormone vasopressin inhibits water diuresis via renal V
 
  <sub>2</sub>receptors. In addition, vasopressin has been demonstrated to cause vasodilation in numerous vascular beds that are mediated by V
 
  <sub>2</sub>, V
 
  <sub>3</sub>, oxytocin and purinergic P2 receptors.

 </paragraph>
                        <paragraph>In patients with vasodilatory shock vasopressin in therapeutic doses increases systemic vascular resistance and mean arterial blood pressure and reduces the dose requirements for norepinephrine. Vasopressin tends to decrease heart rate and cardiac output. The pressor effect is proportional to the infusion rate of exogenous vasopressin. The pressor effect reaches its peak within 15 minutes. After stopping the infusion the pressor effect fades within 20 minutes. There is no evidence for tachyphylaxis or tolerance to the pressor effect of vasopressin in patients.</paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e92904f5-b767-4f54-b7a5-539ba6804e9c">
                     <id root="3532879b-038f-4201-e063-6394a90a9cbd"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Vasopressin plasma concentrations increase linearly with increasing infusion rates from 10 to 200 μU/kg/min. Steady state plasma concentrations are achieved after 30 minutes of continuous intravenous infusion.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Vasopressin does not appear to bind plasma protein. The volume of distribution is 140 mL/kg.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>At infusion rates used in vasodilatory shock (0.01 to 0.1 units/minute), the clearance of vasopressin is 9 to 25 mL/min/kg in patients with vasodilatory shock. The apparent t
 
  <sub>1/2</sub>of vasopressin at these levels is ≤10 minutes.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism</content>
                        </paragraph>
                        <paragraph>Serine protease, carboxipeptidase and disulfide oxido-reductase cleave vasopressin at sites relevant for the pharmacological activity of the hormone. Thus, the generated metabolites are not expected to retain important pharmacological activity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Excretion</content>
                        </paragraph>
                        <paragraph>Vasopressin is predominantly metabolized and only about 6% of the dose is excreted unchanged into urine.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>Pregnancy: Because of a spillover into blood of placental vasopressinase, the clearance of exogenous and endogenous vasopressin increases gradually over the course of a pregnancy. During the first trimester of pregnancy, the clearance is only slightly increased. However, by the third trimester the clearance of vasopressin is increased about 4-fold and at term up to 5-fold. After delivery, the clearance of vasopressin returns to preconception baseline within two weeks.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Indomethacin more than doubles the time to offset for vasopressin’s effect on peripheral vascular resistance and cardiac output in healthy subjects
 
  <content styleCode="italics">[see Drug Interactions (7.2)]</content>.

 </paragraph>
                        <paragraph>The ganglionic blocking agent tetra-ethylammonium increases the pressor effect of vasopressin by 20% in healthy subjects
 
  <content styleCode="italics">[see Drug Interactions (7.3)]</content>.

 </paragraph>
                        <paragraph>Halothane, morphine, fentanyl, alfentanyl and sufentanyl do not impact exposure to endogenous vasopressin. </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_06550c36-ad94-4e94-bbe0-c29f41b921a3">
               <id root="3532879b-0390-4201-e063-6394a90a9cbd"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220401"/>
               <component>
                  <section ID="LINK_6d1be9a3-5b16-4ba6-9a15-833f32992521">
                     <id root="3532879b-0391-4201-e063-6394a90a9cbd"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No formal carcinogenicity or fertility studies with vasopressin have been conducted in animals. Vasopressin was found to be negative in the
 
  <content styleCode="italics">in vitro</content>bacterial mutagenicity (Ames) test and the
 
  <content styleCode="italics">in vitro</content>Chinese hamster ovary (CHO) cell chromosome aberration test. In mice, vasopressin has been reported to have an effect on function and fertilizing ability of spermatozoa.

 </paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
               <component>
                  <section ID="_d5fcf57e-e402-ccca-431c-15f036b6d478">
                     <id root="3532879b-0392-4201-e063-6394a90a9cbd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>No toxicology studies were conducted with vasopressin.</paragraph>
                     </text>
                     <effectiveTime value="20220401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_82bf6753-febe-45a2-9e89-76946e21ead3">
               <id root="3532879b-0393-4201-e063-6394a90a9cbd"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Increases in systolic and mean blood pressure following administration of vasopressin were observed in 7 studies in septic shock and 8 in post-cardiotomy vasodilatory shock.</paragraph>
               </text>
               <effectiveTime value="20220401"/>
            </section>
         </component>
         <component>
            <section ID="LINK_217357e0-5d8a-4088-940e-6d94d296e321">
               <id root="3532879b-0394-4201-e063-6394a90a9cbd"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Vasopressin injection, USP is a clear, colorless solution for intravenous administration available as:</paragraph>
                  <paragraph>NDC 43598-914-06: A carton of 25 single dose vials. Each vial contains vasopressin, USP 1 mL at 20 units/mL.</paragraph>
               </text>
               <effectiveTime value="20220401"/>
               <component>
                  <section ID="LINK_0000bebf-9e0b-493e-bae5-92a84e9557c5">
                     <id root="3532879b-0395-4201-e063-6394a90a9cbd"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title/>
                     <text>
                        <paragraph>Store between 2°C and 8°C (36°F and 46°F). Do not freeze.</paragraph>
                        <paragraph>Vials may be held up to 12 months upon removal from refrigeration to room temperature storage conditions (20°C to 25°C [68°F to 77°F], see USP Controlled Room Temperature), anytime within the labeled shelf life. Once removed from refrigeration, unopened vial should be marked to indicate the revised 12 months expiration date. If the manufacturer's original expiration date is shorter than the revised expiration date, then the shorter date must be used. Do not use vasopressin injection, USP beyond the manufacturer's expiration date stamped on the vial.</paragraph>
                        <paragraph>The storage conditions and expiration periods are summarized in the following table. 
  <br/>
                        </paragraph>
                        <table frame="border" rules="all">
                           <tbody>
                              <tr valign="middle">
                                 <td/>
                                 <td align="center">Unopened 
     <br/>  Refrigerated 2°C to 8°C (36°F to 46°F)
    </td>
                                 <td align="center">Unopened Room Temperature 20°C to 25°C (68°F to 77°F) 
     <br/>  Do not store above 25°C (77°F)
    </td>
                                 <td>Opened (After First Pun cture)</td>
                              </tr>
                              <tr>
                                 <td>1 mL Vial</td>
                                 <td align="center">Until manufacturerexpiration date</td>
                                 <td>12 months or until manufacturer expiration date,whichever is earlier</td>
                                 <td align="center">N/A</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20230401"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_89c86c9c-665a-4d1b-beb1-ca82c17a60cb">
               <id root="3532879b-0396-4201-e063-6394a90a9cbd"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Distributor:
 
  <content styleCode="bold">Dr. Reddy’s Laboratories, Inc.</content>
                  </paragraph>
                  <paragraph>Princeton, NJ 08540</paragraph>
                  <paragraph>
                     <content styleCode="bold">Made in India</content>
                  </paragraph>
                  <paragraph>Revised: 07/2024 
  <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20220401"/>
            </section>
         </component>
         <component>
            <section ID="_b02d5b43-8567-0c0e-1ac7-d49d8f4e0910">
               <id root="3532ac4e-fd21-88a8-e063-6294a90a788a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - OUTER PACKAGE</title>
               <text>
                  <paragraph>NDC 71872-7334-1</paragraph>
                  <paragraph>Vasopressin Injection, USP</paragraph>
                  <paragraph>20 Units per mL</paragraph>
                  <paragraph>1 x 1 mL Single-Dose Vial</paragraph>
                  <paragraph>RX Only</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_3532ac4e-fd20-88a8-e063-6294a90a788a"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241116"/>
               <component>
                  <observationMedia ID="img_3532ac4e-fd20-88a8-e063-6294a90a788a">
                     <text>7334.pdp</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="7334.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>